1574P - Survival prolongation by rationale innovative genomics (SPRING): An international WIN consortium phase I study exploring safety and efficacy of avelumab, palbociclib, and axitinib in advanced non-small cell lung cancer (NSCLC) with integrated genomic and transcriptomic correlates

Benjamin Solomon ,J.J Lee,Fanny Wunder ,Enriqueta Felip ,Catherine Bresson ,Brian Leyland‐Jones ,Eitan Rubin ,Éric Raymond ,Nicolas Girard ,Vladimir Lazar ,Raed Sulaiman ,Jair Bar ,Pierre Saintigny ,Lyudmila Bazhenova ,Jacques Raynaud ,Guy Berchem ,Amir Onn ,Ben Young ,Ana Callejo ,Razelle Kurzrock

doi:10.1093/annonc/mdz260.096

1574P - Survival prolongation by rationale innovative genomics (SPRING): An international WIN consortium phase I study exploring safety and efficacy of avelumab, palbociclib, and axitinib in advanced non-small cell lung cancer (NSCLC) with integrated genomic and transcriptomic correlates

Benjamin Solomon , J.J Lee + Show 18 more

Open Access

https://doi.org/10.1093/annonc/mdz260.096

Copy DOI

Journal: Annals of oncology : official journal of the European Society for Medical Oncology	Publication Date: Oct 1, 2019
Citations: 3

#Expert Testimony #Speaker Bureau + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

1574P - Survival prolongation by rationale innovative genomics (SPRING): An international WIN consortium phase I study exploring safety and efficacy of avelumab, palbociclib, and axitinib in advanced non-small cell lung cancer (NSCLC) with integrated genomic and transcriptomic correlates

Full Text